-
Something wrong with this record ?
In silico and in vitro evaluation of two novel oximes (K378 and K727) in comparison to K-27 and pralidoxime against paraoxon-ethyl intoxication
M. Arshad, MQ. Fatmi, K. Musilek, A. Hussain, K. Kuca, G. Petroianu, H. Kalasz, SM. Nurulain,
Language English Country England, Great Britain
Document type Comparative Study, Journal Article
- MeSH
- Acetylcholinesterase blood chemistry MeSH
- Antidotes chemistry metabolism pharmacology MeSH
- Cholinesterase Inhibitors chemistry metabolism toxicity MeSH
- GPI-Linked Proteins antagonists & inhibitors blood chemistry MeSH
- Protein Conformation MeSH
- Humans MeSH
- Organophosphate Poisoning blood drug therapy enzymology MeSH
- Oximes chemistry metabolism pharmacology MeSH
- Paraoxon analogs & derivatives chemistry metabolism toxicity MeSH
- Pralidoxime Compounds chemistry metabolism pharmacology MeSH
- Pyridinium Compounds chemistry metabolism pharmacology MeSH
- Cholinesterase Reactivators chemistry metabolism pharmacology MeSH
- Molecular Docking Simulation * MeSH
- Protein Binding MeSH
- Binding Sites MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
Organophosphate (OP) poisoning is a major global health issue; while compounds from this group have been used intensively over the last century, an effective antidote is still lacking. Oxime-type acetylcholinesterase (AChE) reactivators are used to reactivate the OP inhibited AChE. Pralidoxime is the only US Food and Drug Administration approved oxime for therapeutic use but its efficacy has been disappointing. Two novel oximes (K378 and K727) were investigated in silico and in vitro and compared with an experimental oxime (kamiloxime; K-27) and pralidoxime. In silico the molecular interactions between AChE and oximes were examined and binding energies were assessed. LogP (predicted log of the octanol/water partition coefficient) was estimated. In vitro the intrinsic ability of the oximes to inhibit AChE (IC50) and their reactivation potency (R50) when used in paraoxon inhibited human RBC-AChE was determined. Molecular docking revealed that K378 and K727 bind to the peripheral site(s) with high binding energies in contrast to the central binding of K-27 and pralidoxime. LogP values indicating that the novel compounds are significantly less hydrophilic than K-27 or pralidoxime. IC50 of K378 and K727 were comparable (0.9 and 1 µM, respectively) but orders of magnitude lower than comparators. R50 values revealed their inability to reactivate paraoxon inhibited AChE. It is concluded that the novel oximes K378 and K727 are unlikely to be clinically useful. The in silico and in vitro studies described allow avoidance of unnecessary in vivo animal work and contribute to the reduction of laboratory animal use.
Department of Biosciences COMSATS Institute of Information Technology Islamabad Pakistan
e Department of Pharmacology and Pharmacotherapy Semmelweis University Budapest Hungary
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033821
- 003
- CZ-PrNML
- 005
- 20181012110016.0
- 007
- ta
- 008
- 181008s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/15376516.2017.1357777 $2 doi
- 035 __
- $a (PubMed)28722512
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Arshad, Maria $u a Department of Biosciences , COMSATS Institute of Information Technology , Islamabad , Pakistan.
- 245 10
- $a In silico and in vitro evaluation of two novel oximes (K378 and K727) in comparison to K-27 and pralidoxime against paraoxon-ethyl intoxication / $c M. Arshad, MQ. Fatmi, K. Musilek, A. Hussain, K. Kuca, G. Petroianu, H. Kalasz, SM. Nurulain,
- 520 9_
- $a Organophosphate (OP) poisoning is a major global health issue; while compounds from this group have been used intensively over the last century, an effective antidote is still lacking. Oxime-type acetylcholinesterase (AChE) reactivators are used to reactivate the OP inhibited AChE. Pralidoxime is the only US Food and Drug Administration approved oxime for therapeutic use but its efficacy has been disappointing. Two novel oximes (K378 and K727) were investigated in silico and in vitro and compared with an experimental oxime (kamiloxime; K-27) and pralidoxime. In silico the molecular interactions between AChE and oximes were examined and binding energies were assessed. LogP (predicted log of the octanol/water partition coefficient) was estimated. In vitro the intrinsic ability of the oximes to inhibit AChE (IC50) and their reactivation potency (R50) when used in paraoxon inhibited human RBC-AChE was determined. Molecular docking revealed that K378 and K727 bind to the peripheral site(s) with high binding energies in contrast to the central binding of K-27 and pralidoxime. LogP values indicating that the novel compounds are significantly less hydrophilic than K-27 or pralidoxime. IC50 of K378 and K727 were comparable (0.9 and 1 µM, respectively) but orders of magnitude lower than comparators. R50 values revealed their inability to reactivate paraoxon inhibited AChE. It is concluded that the novel oximes K378 and K727 are unlikely to be clinically useful. The in silico and in vitro studies described allow avoidance of unnecessary in vivo animal work and contribute to the reduction of laboratory animal use.
- 650 _2
- $a acetylcholinesterasa $x krev $x chemie $7 D000110
- 650 _2
- $a antidota $x chemie $x metabolismus $x farmakologie $7 D000931
- 650 _2
- $a vazebná místa $7 D001665
- 650 _2
- $a cholinesterasové inhibitory $x chemie $x metabolismus $x toxicita $7 D002800
- 650 _2
- $a reaktivátory cholinesterasy $x chemie $x metabolismus $x farmakologie $7 D002801
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a GPI-vázané proteiny $x antagonisté a inhibitory $x krev $x chemie $7 D058851
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a otrava organofosfáty $x krev $x farmakoterapie $x enzymologie $7 D062025
- 650 _2
- $a oximy $x chemie $x metabolismus $x farmakologie $7 D010091
- 650 _2
- $a paraoxon $x analogy a deriváty $x chemie $x metabolismus $x toxicita $7 D010261
- 650 _2
- $a pralidoximové sloučeniny $x chemie $x metabolismus $x farmakologie $7 D011220
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a konformace proteinů $7 D011487
- 650 _2
- $a pyridinové sloučeniny $x chemie $x metabolismus $x farmakologie $7 D011726
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Fatmi, Muhammad Qaiser $u a Department of Biosciences , COMSATS Institute of Information Technology , Islamabad , Pakistan.
- 700 1_
- $a Musilek, Kamil $u b Department of Chemistry , Faculty of Science, University of Hradec Kralove , Hradec Kralove , Czech Republic. c University Hospital in Hradec Kralove , Hradec Kralove , Czech Republic.
- 700 1_
- $a Hussain, Alamdar $u a Department of Biosciences , COMSATS Institute of Information Technology , Islamabad , Pakistan.
- 700 1_
- $a Kuca, Kamil $u b Department of Chemistry , Faculty of Science, University of Hradec Kralove , Hradec Kralove , Czech Republic. c University Hospital in Hradec Kralove , Hradec Kralove , Czech Republic.
- 700 1_
- $a Petroianu, Georg $u d Department of Cellular Biology & Pharmacology, Herbert Wertheim College of Medicine , Florida International University , Miami , FL , USA.
- 700 1_
- $a Kalasz, Huba $u e Department of Pharmacology and Pharmacotherapy , Semmelweis University , Budapest , Hungary.
- 700 1_
- $a Nurulain, Syed Muhammad $u a Department of Biosciences , COMSATS Institute of Information Technology , Islamabad , Pakistan.
- 773 0_
- $w MED00007380 $t Toxicology mechanisms and methods $x 1537-6524 $g Roč. 28, č. 1 (2018), s. 62-68
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28722512 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181012110508 $b ABA008
- 999 __
- $a ok $b bmc $g 1340311 $s 1030815
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 28 $c 1 $d 62-68 $e 20170804 $i 1537-6524 $m Toxicology mechanisms and methods $n Toxicol Mech Methods $x MED00007380
- LZP __
- $a Pubmed-20181008